Question 1

How does EquitAI evaluate OKYO Pharma Limited's (OKYO) valuation and Stock DNA?

Accepted Answer

OKYO Pharma Limited (OKYO) trades at $1.47 with an EquitAI Valuation DNA score of 5/10 and Quality score of 3/10. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does OKYO Pharma Limited (OKYO) operate in?

Accepted Answer

OKYO Pharma Limited (OKYO) is classified under the Healthcare sector within the Biotechnology industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Biotechnology peers and broader Healthcare market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for OKYO Pharma Limited (OKYO)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $5.0 for OKYO Pharma Limited (OKYO), representing an implied 240.1% upside from its current trading level of $1.47 with an average rating of Buy based on 2 analyst ratings. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does OKYO pay dividends or capital distributions?

Accepted Answer

OKYO Pharma Limited does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

Question 5

Who are OKYO Pharma Limited's (OKYO) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include OCUL, OCS, EYPT, KPRX. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's OKYO analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

OKYO - OKYO Pharma Limited Stock Analysis & Valuation

OKYO Pharma Limited

Requires Baseline Research

Requires Baseline Research